AC Immune (STU:IMR) Accounts Payable: €1.45 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IMR AC Immune SA STU:IMR
32 GF Score
Price €2.10
GF Value €0.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Accounts Payable?

AC Immune STU:IMR -0.95% 32 Accounts Payable is €1.45 Mil as of Mar. 2026. GuruFocus rates STU:IMR with a GF Score™ of 32/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 6 warning signs investors should review.

AC Immune's Accounts Payable for the quarter that ended in Mar. 2026 was €1.45 Mil.

AC Immune's quarterly Accounts Payable increased from Sep. 2025 (€1.68 Mil) to Dec. 2025 (€2.22 Mil) but then declined from Dec. 2025 (€2.22 Mil) to Mar. 2026 (€1.45 Mil).

AC Immune's annual Accounts Payable increased from Dec. 2023 (€1.78 Mil) to Dec. 2024 (€2.85 Mil) but then declined from Dec. 2024 (€2.85 Mil) to Dec. 2025 (€2.22 Mil).

AC Immune Accounts Payable Historical Data

* Premium members only.

The historical data trend for AC Immune's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune Accounts Payable Chart

AC Immune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 0.94 1.78 2.85 2.22

AC Immune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 2.91 1.68 2.22 1.45
STU:IMR
32GF Score
AC Immune SA STU:IMR
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AC Immune Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.45 Mil mean?
AC Immune (STU:IMR) has a Accounts Payable of €1.45 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on AC Immune and its competitors.
Is AC Immune's Accounts Payable too high?
AC Immune's current Accounts Payable is €1.45 Mil. Overall, AC Immune has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Accounts Payable compare to NAUT and IVVD?
AC Immune's Accounts Payable of €1.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on AC Immune and its competitors. AC Immune's current Accounts Payable is €1.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (STU:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €2.10 — trading 222.3% above its estimated fair value. The current Accounts Payable is €1.45 Mil. AC Immune's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For AC Immune (STU:IMR), the current Accounts Payable is €1.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (STU:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of €2.10 is trading 222.3% above its estimated GF Value™ of €0.65. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for STU:IMR:

  • Accounts Payable: €1.45 Mil
  • GF Value™: €0.65 vs. price of €2.10 (222.3% above fair value)
  • GF Score™: 32/100 with 6 warning signs

No single metric tells the full story. See the STU:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges ACIU:USA
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
32GF Score

Get the complete analysis for STU:IMR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price
€0.65
GF Value